China NewCo Summit to Unveil Full-Chain Insights from 25 Industry Leaders – Early Bird Registration Ends in 2 Days!
If you areInvestor, seeking to participate in the NewCo model, connect with executives from USD-denominated funds and innovative drug companies, and identify high-quality investment targets;
If you areInnovative Pharmaceutical Companies, to understand the NewCo model, connect with NewCo investors, and expand financing channels and cooperation opportunities;
If you areLarge Pharmaceutical Companies, with BD needs, aiming to explore and implement the NewCo model in practice,Connect with NewCo’s investors, seekingGrowth Opportunities;
December 6Shanghai · Zhangjiang
China NewCo Summit
Don't miss out! 🎉🎉
■ The audience is more specialized.Precision AlignmentNewCoChain Networking！
Last 2 Days for Early Bird Pricing (Ends December 1) ！
1. Conference Ticket: CNY 3,800 per company; Early Bird Price: CNY 3,100 per company (valid until December 1) (limited to a maximum of 3 attendees, including one dinner seat)
2. Conference Attendance + NewCo Consultation & Diagnosis Session and Dinner Networking Ticket: CNY 5,800 per company; Early Bird Price: CNY 4,600 per company (until December 1) (Limited to a maximum of 3 attendees, including dinner for all 3)
Conference Overview
Meeting Name:China NewCo Summit
Meeting Time:December 6
Conference Venue:China · Shanghai Zhangjiang
Organizer:VCBeat, Button Capital
Supporting Organizations:Asymchem Laboratories (Tianjin) Co., Ltd., Drug Hunter Club, AllBright Law Offices, Beijing Meilian Global International Travel Service Co., Ltd., Fudan University School of International Finance
Conference Value
■ Helping domestic innovative drug investors,Accumulate NewCo Insights, Empower Portfolio Companies, seeking targets with NewCo potential.
■ Assist in identifying US dollar funds for Chinese NewCo assets,Understanding the Domestic Ecosystem and Connecting with Potential Targets。
Attendees
Event Agenda
Li Datao | Founder of VCBeat
Jie Lun Zhu | Partner, Button Capital
Zuo Honggang | CFO of Weili Zhibo
Tea Break
* Listed alphabetically by guests' surnames
Lunch
Fang Lei | Vice President of R&D at Lepu Biopharma and General Manager of Lepu Chuangyi
Li Rui | Partner, Niukou Capital (Moderator)
Li Jia | Partner at Langsheng Investment
Wu Jie | Head of MPM Capital Asia-Pacific
Wu Xuetao | Partner at VCBeat (Moderator)
Liu Dan | Managing Partner, Pivotal bioVenture
Liu Tingting | Senior Lawyer, AllBright Law Offices
Sun Linghao |Managing Director, MPCi at Matrix Partners China
Xiong Jian | Partner at Niukou Capital (Moderator)
* Listed alphabetically by guests' surnames
Tea Break
Liu Yiming | Managing Partner, Cooley LLP
*Listed alphabetically by guests' surnames
Speaker
Li Rui
Partner, Button Capital
Personal Profile:
Li Datao
Founder of VCBeat (Danhuang Technology)
Founded in May 2014, Eggshell Technology/VCBeat is committed to becoming an industry service organization with global influence, focusing on reporting and researching the transformation of the life and health industry driven by technology at the information level, and using its pen to document and promote the great changes taking place in this land.
Zhu Jielun
Partner, Button Capital
A seasoned industry-finance expert in the life sciences sector with over 20 years of experience in the biopharmaceutical capital markets. He graduated from Harvard Business School as a Baker Scholar. He previously served as CFO of I-Mab Biopharma and Fapon Biotech. He led I-Mab’s successful listing on NASDAQ, driving its market capitalization from $800 million to $7 billion, ranking it among the top five most valuable next-generation biotechnology companies in China. His outstanding performance in the healthcare industry has earned him repeated recognition as Best CFO by institutional investors. Prior to this, he served as Head of Asia Pacific Healthcare at Jefferies, where he facilitated cross-border M&A and financing transactions totaling over $10 billion. He also held healthcare industry leadership roles at Deutsche Bank and UBS, making significant contributions to the global healthcare sector. Currently, he focuses on advancing the “NewCo” model in the biotechnology industry, dedicated to incubating early-stage startups and expanding into international markets, helping domestic biotech enterprises go global.
Zuo Honggang
Personal Profile:
Over 20 years of professional experience in building management systems, enhancing operational efficiency, and managing finance and capital markets for leading enterprises in China, the United States, and other regions. Possesses experience with IPOs on the US and Hong Kong stock exchanges and has served as CFO of listed companies. Previously held positions such as CFO, Chief Strategy Officer, Executive Director, and Vice President at renowned domestic and international companies including Genetron Health, Jingrui Education, General Electric (GE), and PwC. Has over eight years of experience in equity investment and capital markets at financial institutions such as Goldman Sachs. Holds an MBA from the MIT Sloan School of Management.
Chen Gang
LYFE Capital
Managing Partner
Prior to joining Zhouling Capital, he served successively as a Senior Consultant at L.E.K. Consulting, Investment Director at VV Capital, and Investment Director at Aland, accumulating 15 years of experience in healthcare investment and consulting. Through years of professional practice, Chen Gang has established extensive industry resources across China. He holds an MBA from the Kellogg School of Management at Northwestern University, having previously graduated from Fudan University with a degree in Clinical Medicine.
Liu Tianran
Vertex Ventures
Partner
Deng Jianliang
Tianhui Capital
Partner
Previously held positions at institutions such as Yangtze River Pharmaceutical Group, with over 10 years of experience in business development (BD) and investment management within the pharmaceutical industry. Spearheaded the establishment of Tianhui’s investment research framework and participated in creating Tianhui’s “Fund + Alliance + Ecosystem” investment development model. Led or participated in investment cases including Nanomicro Tech (688690.SH), Anhui Wanbang Medicine (301520.SZ), Majino Genomics, Terui Pharmaceutical, Hanhai New Enzyme, Simcere Diagnostics, Maiji Biopharma, Yannuo Pharma, Luoqi Biologics, Huijian Technology, and Baisai Biologics.
VCBeat
6 Dimensions Capital
Managing Partner
Managing Partner of AllBright YuCheng and Head of its Shanghai Office, Mr. Hua joined AllBright Capital as a founding member in 2012 (AllBright Capital merged with YuCheng Capital in May 2017 to form AllBright YuCheng). Over the past 12 years, Mr. Hua has led and participated in numerous transactions in the fields of biotechnology, medical devices, and healthcare services, including Jiecheng Medical, Innovent Biologics (1801.HKEX), Hua Medicine (2552.HKEX), Kangtai Biological Products (300601), Guoke Hengtai (301370), Neusoft Medical, Gracell Biotechnologies (GRCL.Nasdaq), Yikang Medical, Xikang Cloud Hospital (9686.HKEX), Grail, and Mubao Shengke. Mr. Hua began his venture capital career in 2007 when he joined the Shanghai Representative Office of Fidelity Asia Funds (now renamed as STOA Capital).
Fang Lei
Vice President of R&D, Lepu Biopharma
General Manager of Lepu Chuangyi
With over 10 years of experience in the field of oncology clinical drug development, Dr. Fang is an expert in immunology, development strategies for innovative drugs, early-stage clinical trials, and translational medicine. Prior to joining Lepu Biopharma, Dr. Fang served as Co-founder and Executive Director of R&D at I-Mab (NASDAQ: IMAB) from 2015 to 2020, and previously held positions as Researcher and Scientist at GlaxoSmithKline (Shanghai) R&D Co., Ltd. from 2010 to 2015. He received his Bachelor’s degree in Biotechnology from Hebei University in 2004 and his Ph.D. in Cell Biology from the Chinese Academy of Sciences in 2010.
Wu Xuetao
Eggshell Technology (VCBeat)
Partner
Wu Jie
MPM Capital
Head of Asia-Pacific Region
Li Jia
LanSheng Investment
Partner
• Partner at Longsheng Investment, overseeing the healthcare and wellness sector
• Formerly served as Executive Vice President of Dayou Huaxia Biotechnology Co., Ltd., founded by Professor Lieping Chen
• Former Senior Vice President of Crown Bioscience
• Formerly Senior Scientist at Exelixis (a biotechnology company focused on oncology and metabolic diseases)
• Former Scientist at Zyomyx (an antibody chip development company)
• Ph.D. in Molecular Physiology and Biophysics, University of Virginia
• University of Alberta, M.Sc. Student in Biochemistry
• UCSF Cheng’s Scholar
• Bachelor of Science in Chemistry, Nanjing University
Xiong Jian
Button Capital
Partner
A senior R&D expert and BD transaction specialist in the biopharmaceutical sector, with over 15 years of experience in new drug development and nearly 10 years in business development. A graduate of Fudan University, he has long been employed at WuXi AppTec, where he served as Business Head of the Overseas Business Department and as BD Lead/Senior Director of the Domestic Drug Discovery Services Unit (DDSU). As the primary inventor, he led the preclinical development of three Class 1 new drugs, one of which is a first-in-class (FIC) anti-infective agent currently at the New Drug Application (NDA) stage and expected to receive marketing approval soon. Additionally, he spearheaded more than 60 new drug BD transactions involving diverse molecular formats, including small molecules, peptides, and peptide-drug conjugates (PDCs), contributing significantly to the innovative transformation of traditional Chinese pharmaceutical companies and the global expansion of Chinese biotech firms. Currently, he is focused on promoting the “NewCo” model in the biopharmaceutical industry, dedicated to incubating early-stage startups and expanding into international markets to help local biopharmaceutical enterprises go global.
Chen Youchen
Vice President of Finance, Harbour BioMed
Head of Strategy and Capital Markets
Personal Profile:
Holding a Bachelor of Laws from Fudan University and an MBA from the McDonough School of Business at Georgetown University, YC is currently pursuing further studies at Harvard Medical School. YC joined Harbin Pharmaceutical Group (Harbin Pharma) in 2023, primarily overseeing financial management, strategic planning, global business development, investment and financing, as well as investor relations. Previously, he served as Chief Financial Officer at a clinical-stage radiopharmaceutical company. Prior to that, YC was a Vice President on Credit Suisse’s China Investment Banking team, providing capital markets services for strategic and financing transactions to mid-to-large cap biopharmaceutical, healthcare, and technology companies across the Asia-Pacific region. Before returning to Credit Suisse, YC served as Head of Corporate Finance at MedTech Technology (2158.HK), where he assisted the company in completing its Hong Kong IPO, raising over USD 600 million. Prior to his MBA, YC held various positions at CITIC Capital and KPMG.
Liu Dan
Pivotal bioVenture
Managing Partner
Oversees life sciences investment operations in China. Previously, he served as Senior Partner, Managing Partner, and Investment Committee Member at CDH Investments, where he led investments across multiple healthcare-focused funds. His portfolio includes dozens of high-quality companies such as GemPharmatech (688046.SH), HitGen (688222.SH), I-Mab (IMAB.O), Strong Biotech·Maixin Bio (300406), YZY Biopharma (02496.HK), Fanovent Bio, Singlera Genomics, and Qitan Technology. Prior to joining CDH Investments, Dr. Liu worked at Bain & Company, primarily engaging in management consulting within the healthcare sector, where he served and led strategic projects for several large multinational pharmaceutical and medical device companies. With nearly 20 years of experience spanning scientific research, business, management, consulting, and investment in the life sciences industry, he also serves as a council member and senior expert for various government bodies and industry associations, and as a review expert for numerous provincial and municipal science, technology, and talent programs. He has been repeatedly recognized on prestigious industry lists, including “40 Under 40 Investors” and “Top 10 Investment Figures in Healthcare and Life Sciences of the Year.”
Sun Linghao
Matrix Partners China MPCi
Managing Director
Joined Matrix Partners China in 2016, focusing on early-to-mid-stage investments in the healthcare sector. Graduated from the School of Pharmacy at Fudan University, with extensive experience in investment and financing across biopharmaceuticals, medical devices, and the upstream and downstream segments of the healthcare industry chain. Honors received include Top 15 Best Healthcare Investors by Qimingpian, 36Kr’s 36 Under 36 Outstanding Investors, Top 20 China Healthcare Investors by 36Kr, Young Outstanding Investor by Touzijia, Youth Healthcare Investor by Zhuoyue Bang, and Annual Young Healthcare Investor by VCBeat.
Cheng Gang
YuanSheng Ventures
Partner
He earned his bachelor’s degree from Tsinghua University and his Ph.D. from Rice University in the United States, followed by postdoctoral research in tumor biology at Massachusetts General Hospital, affiliated with Harvard Medical School. Upon returning to China, he has been working in the biomedical industry. Prior to joining OrbiMed Asia Partners, he served as Principal Investigator in the In Vivo Pharmacology Department at BeiGene Ltd., Head of the China Team in the Clinical Oncology Biomarker R&D Department at Roche/Genentech, and Chief Scientific Officer at Novogene Corporation.
Liu Tingting
AllBright Law Offices
Senior Attorney
Liu Yiming
Managing Partner, Cooley LLP
Personal Profile:
Liu Yiming frequently represents life sciences and healthcare company clients, providing legal services for various strategic transactions across all stages of the corporate lifecycle, including licensing and collaboration agreements, initial public offerings (IPOs) in Hong Kong and the United States, cross-border mergers and acquisitions, private equity financings, and joint ventures. Mr. Liu’s recent representative transactions include Qiming Venture Partners’ investment in NewCo Vignette Bio; CanSino Biologics’ asset purchase agreement with GSK; ArriVent BioPharma’s exclusive option and global license agreement with AstraZeneca; Mingji Biopharma’s license agreement with AbbVie; Zhenrong Pharma’s exclusive licensing collaboration with Roche; Brii Biosciences’ asset purchase agreement with VBI Vaccines; and Asymchem Laboratories’ acquisition of Pfizer’s former UK manufacturing site. Mr. Liu earned his Juris Doctor degree from Columbia University in the United States, a Master of Science in Molecular, Cellular, and Developmental Biology and a Master of Health Services Administration from the University of Michigan, and a Bachelor of Science in Biology from Fudan University. He is admitted to practice law in the State of New York and is a registered foreign lawyer in Hong Kong.
Bu Qianqian
IIntelliPro Senior Partner
Personal Profile:
Global Senior Partner, Life Sciences and Healthcare, at IPG (InterGreat Partners), leading an international team of over 100 professionals. With more than a decade of extensive experience in executive search, she specializes in the global healthcare industry, offering unique insights particularly in pharmaceuticals and medical devices. Blair excels in strategic planning and international cooperation across key markets including China, the United States, Singapore, and Europe, playing a pivotal role in IPG’s globalization and deep industry engagement. Committed to advancing the internationalization of Chinese healthcare enterprises, she provides comprehensive talent acquisition solutions, connects global executive resources, and facilitates transactions, financing, and market entry, significantly enhancing their international competitiveness. Additionally, she has established teams in major U.S. healthcare hubs such as Boston, Maryland, and San Diego, providing critical talent support for local industry development.
Anthony Yeh
Bio-Thera
CSO & Head of China BD
Personal Profile:
Dr. Anthony Yeh is Chief Strategy Officer and Head of China business development (BD) of Biosion. He has ~20 years of biopharmaceutical research and industry experience in strategy, capital market and business development.
Before Biosion, Dr. Yeh was Vice President, Head of Corporate Strategy and Capital Market at CStone Pharmaceuticals. During his 3+ years at CStone, Dr. Yeh served different leadership roles in helping to build CStone through IPO and eventually to commercialization. Before CStone, Dr. Yeh was Regional Head of Business Economics and Strategy at Abbott. Before Abbott, Dr. Yeh was engagement manager at L.E.K. Consulting where he specialized in life sciences strategy, commercial due diligence, and M&A.
Dr. Yeh holds a Ph.D. in Molecular Medicine from University of Oxford and a Bachelor of Science (honors) from Queensland University of Technology.
Megan Xu
Novartis
Search & Evaluation Director
Personal Profile:
Prior to joining Novartis, she had over eight years of experience in investment banking, during which she was based in Hong Kong and New York and participated in several financing and M&A transactions. Megan holds a degree from Cornell University in the United States.
*Guests listed in order of appearance
Partial Registered Audience
eppendorf BPU commercial head
CFO, Suzhou Huayi Lejian Biotechnology Co., Ltd.
Sanjiang Capital, Senior Investment Manager
Johnson & Johnson Innovative Medicine, Associate Director of Innovation Incubation
JLABS @ Shanghai Head
Hony Capital, Director
Marketing Manager, Bohe Innovation Center
Partner, Mayer Brown LLP
Director, Mainstream Source Biotechnology
As Far as Private Equity Investment
Xinglian Peptide VP
Investment Manager, Mian Capital / Introvert Fund
Vice President, Tongyuan Kang Medicine
Siqi Culture Media, Key Account Manager
Flagship Pioneering Analyst
Morningside Venture Capital, Investment Manager
Zelgen Pharmaceuticals, BD Director
Johnson & Johnson Regional Scientific Program Lead
CR Double-Crane Pharmaceuticals Supervisor
Ideals BD
KEWANG Pharma BD
Expedition Therapeutics BD
KeWang Medicine Head of BD
Rehab Capital, Investment Director
GeekGene COO & CBO
Huichuan Capital, Partner
Xinghao Pengbo, Project Management Manager
Jichuan Pharmaceutical, Vice General Manager
TBD Head
Yaotang Bio BD VP
Head of Business Development, CanSino Biologics
Novartis Search & Evaluation Director
Roche Pharmaceuticals (China) BD AD
CSPC Pharmaceutical Group, VP of Business Development
Partner, Longma Peak Ventures
J.P. Morgan China, Vice President
Managing Director, Huagai Capital
CR Double-Crane CBO
President, Fuqing Asset Management
Probe Capital Managing Director
Qingtong Capital IR
Shanghai Hanyuan, Senior Investment Manager
Hansoh Pharmaceutical International Business Export Manager
Boxi Pharma, Managing Director
CEO of Weiguang Gene
MegaRobo, Director of Laboratory Management
VBInsight Partner
Index Capital, Senior Manager, Trading Execution Department
Kang Shida, Investment Manager
United Future Private Equity Fund, Investment Director
Yudao Bio BD
Deputy Director, MedShip Biopharmaceuticals (Nanjing) Co., Ltd.
......
